Search for drugs:
Typing the drug name to query
PEGINTERFERON ALFA-2B
DIR Classification
Classification:Less-DIR concern
Severity Score:1
Description in Drug Labeling: View Full Labeling: SPL in DailyMed | PDF
- ADVERSE REACTIONS
- Postmarketing Experience
- The following adverse reactions have been identified during post-approval use of PegIntron therapy. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
- Blood and Lymphatic System Disorders
- Pure red cell aplasia, thrombotic thrombocytopenic purpura
- Cardiac Disorders
- Palpitations, pericarditis
- Ear and Labyrinth Disorders
- Hearing loss, vertigo, hearing impairment
- Endocrine Disorders
- Diabetic ketoacidosis, diabetes
- Eye Disorders
- Vogt-Koyanagi-Harada syndrome, serous retinal detachment
- Gastrointestinal Disorders
- Aphthous stomatitis
- General Disorders and Administration Site Conditions
- Asthenic conditions (including asthenia, malaise, fatigue)
- Immune System Disorders
- Cases of acute hypersensitivity reactions (including anaphylaxis, angioedema, urticaria); Stevens-Johnson syndrome, toxic epidermal necrolysis, systemic lupus erythematosus, erythema multiforme
- Infections and Infestations
- Bacterial infection including sepsis, Hepatitis B virus reactivation in HCV/HBV co-infected patients
- Metabolism and Nutrition Disorders
- Dehydration, hypertriglyceridemia
- Musculoskeletal and Connective Tissue Disorders
- Rhabdomyolysis, myositis
- Nervous System Disorders
- Seizures, memory loss, peripheral neuropathy, paraesthesia, migraine headache
- Psychiatric Disorders
- Homicidal ideation
- Respiratory, Thoracic, and Mediastinal Disorders
- Pulmonary hypertension, pulmonary fibrosis
- Renal and Urinary Disorders
- Renal failure, renal insufficiency
- Skin and Subcutaneous Tissue Disorders
- Psoriasis
- Vascular Disorders
- Hypertension, hypotension
Postmarketing Surveillance
Contingency Table:
Current Drug
Other Drugs
Rhabdomyolysis
60
42852
Other ADRs
21209
14096070
Odds Ratio = 0.931
Drug Property Information
ATC Code(s):
- L03AB60 - peginterferon alfa-2b
- L03AB - Interferons
- L03A - IMMUNOSTIMULANTS
- L03 - IMMUNOSTIMULANTS
- L - ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
- L03AB10 - peginterferon alfa-2b
- L03AB - Interferons
- L03A - IMMUNOSTIMULANTS
- L03 - IMMUNOSTIMULANTS
- L - ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Active Ingredient:peginterferon alfa-2b
Active Ingredient UNII:G8RGG88B68
Drugbank ID:DB00022
PubChem Compound:N/A
CAS Number:215647-85-1
Dosage Form(s):kit
Route(s) Of Administrator:
Daily Dose:
- 0.0075 mg/day L03AB10
Chemical Structure: 
SMILE Code:
-
-
Reference
COHORT STUDY:
N/AOTHER REFERENCE(S):
1: Rhabdomyolysis associated with the co-administration of daptomycin and pegylated interferon α-2b and ribavirin in a patient with hepatitis C.
[Colomba Claudia,Rubino Raffaella,Siracusa Lucia,Mazzola Giovanni,Titone Lucina]J Antimicrob Chemother.2012 Jan;67(1):249-50. doi: 10.1093/jac/dkr398. Epub 2011 Sep 29. PMID: 21965434
Disclaimer:
The content of this database of rhabdomyolysis is intended for educational and scientific research purposes only. It is not intended as a substitute for professional medical advice, diagnosis or treatment.
The views presented in this website do not necessarily reflect current or future opinion or policy of the US Food and Drug Administration. Any mention of commercial products is for clarification and not intended as endorsement.